Deadline Approaching: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 12, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECU.
- 06/26/2025
|
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – TEM
- SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI's top executives with violations of the Securities Exchange Act of 1934.
- 06/26/2025
|
TEMPUS AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
- NEW ORLEANS, June 25, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
- 06/25/2025
|
Ambry Genetics' CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
- ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of the Ambry CARE Program® (CARE) for hereditary cancer risk assessment has been published in the Journal of the National Comprehensive Cancer Network. The study, “Validation of a Digital Tool that Uses National Testing Guidelines to Identify Individuals at Risk fo.
- 06/25/2025
|
Tempus AI Is Well Worth Its Price Tag
- Tempus AI's innovation in genomics, data, and applications makes the company well positioned to become a contender in the AI healthcare space. Strong innovation is clearly translating into their financial metrics as revenue growth and margin expansion are promising signs. Guidance was strong as revenue growth is expected to accelerate and the company expects to be adjusted EBITDA positive this year.
- 06/25/2025
|
TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
- NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
- 06/24/2025
|
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or “the Company”) (NASDAQ: TEM) and certain of its officers.
- 06/24/2025
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class Action
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). Tempus investors have until August 12, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR TEMPUS.
- 06/24/2025
|
Law Offices of Howard G. Smith Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class Action
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). Tempus investors have until August 12, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPAT.
- 06/23/2025
|
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
- GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.
- 06/23/2025
|
TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm
- LOS ANGELES , June 23, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/23/2025
|
TEMPUS AI, INC. (NASDAQ: TEM) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Tempus AI, Inc. Investors of Upcoming Deadline
- NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit?
- 06/23/2025
|
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Announces that Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
- SAN DIEGO , June 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the "Class Period"), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v.
- 06/23/2025
|
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
- SAN DIEGO, June 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with violations of the Securities Exchange Act of 1934.
- 06/21/2025
|
TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
- NEW YORK and NEW ORLEANS , June 20, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inclusive (the "Class Period").
- 06/20/2025
|
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK , June 20, 2025 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the "Class Period").
- 06/20/2025
|
Securities Fraud Investigation Into Tempus AI, Inc. (TEM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TEMPUS AI, INC. (TEM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On May 28, 2025, S.
- 06/20/2025
|
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
- SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Tempus AI business and prospects resulting in its stock trading at inflated prices.
- 06/20/2025
|
Tempus AI, Inc. (TEM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at how.
- 06/20/2025
|
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
- TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.
- 06/20/2025
|
Tempus AI, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information Abou the Pending Class Action Against TEM
- SAN DIEGO , June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.
- 06/20/2025
|
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. (NASDAQ: TEM)
- NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a complaint has been filed in the United States District Court for the Eastern District of Illinois on behalf of investors (the “Class”) who purchased or acquired the common stock of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) between August 6 , 202 4 and May 27 , 202 5, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers (the “Complaint”). Should You Join This Class Action Lawsuit?
- 06/19/2025
|
TEMPUS AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
- NEW ORLEANS, June 18, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI , Inc. (NasdaqGS: TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
- 06/18/2025
|
Securities Fraud Investigation Into Tempus AI, Inc. (TEM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TEMPUS AI, INC. (TEM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 28, 2025, Spruce Point Capital published a report alleging, among oth.
- 06/18/2025
|
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or “the Company”) (NASDAQ: TEM) and certain of its officers.
- 06/18/2025
|
INVESTOR ALERT: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead the Tempus AI Class Action Lawsuit - TEM
- SAN DIEGO , June 18, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v.
- 06/18/2025
|
TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
- NEW YORK and NEW ORLEANS, June 18, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
- 06/18/2025
|
Tempus to Participate in TD Cowen's 4th Annual Tools/Dx Revolution Conference
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in TD Cowen's/Securities' 4th Annual Tools/Dx Revolution conference. The event is taking place on June 22 - 25, 2025, in Dana Point, California. Jim Rogers, Chief Financial Officer of Tempus, will join the panel “Acing AI – How To Play The Platforms” on June 23. About Tempus Tempus is a technology company advancing precision me.
- 06/17/2025
|
TEMPUS AI SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
- NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the.
- 06/16/2025
|
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. (TEM)
- NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois on behalf of all persons or entities who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) securities between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”).
- 06/16/2025
|
TEM Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Tempus AI, Inc. Class Action
- SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ:TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.
- 06/16/2025
|
TEM Investors Have Opportunity to Lead Tempus AI, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--TEM Investors Have Opportunity to Lead Tempus AI, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
- 06/16/2025
|
TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm
- NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 06/13/2025
|
TEM Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Tempus AI, Inc. Class Action
- SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.
- 06/13/2025
|
TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
- NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public.
- 06/13/2025
|
Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025
- MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Shamis & Gentile, P.A: To: All persons or entities who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ:TEM) common stock between August 6, 2024 and May 27, 2025, inclusive. You are hereby notified that the class action lawsuit Shouse v.
- 06/13/2025
|
Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach
- TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.
- 06/13/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
- NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc.("Tempus" or the "Company") (NASDAQ:TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/13/2025
|
Shareholder Alert: Robbins LLP Informs Investors of the Tempus AI, Inc. Class Action
- SAN DIEGO , June 13, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.
- 06/13/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Shareholders to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 06/12/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
- NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/12/2025
|
Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research. The collaboration leverages Tempus' AI-powered data analytics platform, Lens, to analyze and.
- 06/12/2025
|
Protect Your Investment: Contact Levi & Korsinsky About the Tempus AI, Inc. (TEM) Investigation
- NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/11/2025
|
Tempus AI, Inc. (TEM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 06/11/2025
|
Shareholders Alert: Investigation Into Tempus AI, Inc. (TEM) - Contact Levi & Korsinsky to Protect Your Rights
- NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/11/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
- NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc.("Tempus" or the "Company") (NASDAQ:TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/11/2025
|
Levi & Korsinsky Investigating Whether Tempus AI, Inc. (TEM) Misled Investors - Securities Law Violations Possible
- NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/10/2025
|
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
- NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ:TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Tempus AI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 06/10/2025
|
Investigation Underway: Tempus AI, Inc. (TEM) - Contact Levi & Korsinsky Over Securities Law Violations
- NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/10/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages Tempus AI, Inc. (TEM) Shareholders to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 06/10/2025
|
ATTENTION TEM Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/10/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
- NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/10/2025
|
Levi & Korsinsky Launches Fraud Investigation on Behalf of Tempus AI, Inc. (TEM) Shareholders
- NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/09/2025
|
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?
- Tempus AI TEM surged 12.5% in the first week of June, outperforming the broader market and the benchmarks by a wide margin. This rally came largely on the heels of investors' positive reaction to two back-to-back innovations from the company.
- 06/09/2025
|
ATTENTION TEM Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/09/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
- NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc.("Tempus" or the "Company") (NASDAQ:TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/09/2025
|
Ongoing Securities Investigation into Tempus AI, Inc. (TEM) - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/09/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Tempus AI, Inc. (TEM) And Encourages Shareholders to Connect
- NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 06/09/2025
|
Lost Money on Tempus AI, Inc. (TEM)? Contact Levi & Korsinsky About Investigation
- NEW YORK, NY / ACCESS Newswire / June 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/08/2025
|
Lost Money on Tempus AI, Inc. (TEM)? Possible Fraud - Contact Levi & Korsinsky Today
- NEW YORK, NY / ACCESS Newswire / June 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/08/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages Tempus AI, Inc. (TEM) Stockholders to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 06/08/2025
|
Lost Investment in Tempus AI, Inc. (TEM)? Levi & Korsinsky Launches Securities Fraud Investigation
- NEW YORK, NY / ACCESS Newswire / June 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/07/2025
|
TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
- NEW YORK, June 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public.
- 06/07/2025
|
I'm Still Bullish On Tempus AI
- TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM's main bet is now on AI for healthcare applications. I believe TEM's main business moat is its vast and rapidly growing data, which can be leveraged for AI. This is how TEM has sustained its impressive revenue growth. For example, it's integrating Ambry and Deep 6 to expand hereditary testing and add millions of records to its dataset. This strengthens Tempus AI's use cases.
- 06/07/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
- NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/07/2025
|
Why Shares of Tempus AI Are Jumping Higher This Week
- Rebounding from their 11.8% decline last week, shares of Tempus AI (TEM 6.49%) are starting June on an auspicious note. In addition to the company dropping two announcements over last weekend, investors responded to TD Cowen commentary addressing Spruce Point's recently released critical report of the company that's specializing in artificial intelligence (AI) solutions for the healthcare industry.
- 06/06/2025
|
Protect Your Investment: Contact Levi & Korsinsky About the Tempus AI, Inc. (TEM) Investigation
- NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/06/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
- NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/06/2025
|
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
- TEM's rapid growth and cost discipline are paving the way for a positive adjusted EBITDA in 2025.
- 06/06/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Investors to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 06/06/2025
|
Lost Money on Tempus AI, Inc. (TEM)? Contact Levi & Korsinsky About Investigation
- NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/05/2025
|
Rosen Law Firm Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
- NEW YORK , June 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public. So What: If you purchased Tempus AI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 06/05/2025
|
3 AI Stocks Flying Under the Radar
- Outside of the big-time AI players, several companies with notable AI exposure, including Tempus AI, SoundHound AI, and Innodata, have been seemingly overlooked by many.
- 06/05/2025
|
Fraud Investigation: Levi & Korsinsky Investigates Tempus AI, Inc. (TEM) on Behalf of Shareholders
- NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/05/2025
|
Tempus AI, Inc. (TEM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 06/05/2025
|
Shareholders Alert: Investigation Into Tempus AI, Inc. (TEM) - Contact Levi & Korsinsky to Protect Your Rights
- NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/05/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
- NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc.("Tempus" or the "Company") (NASDAQ:TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/05/2025
|
Lost Money on Tempus AI, Inc. (TEM)? Contact Levi & Korsinsky About Investigation
- NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/04/2025
|
TEMPUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Tempus AI, Inc. on Behalf of Tempus Stockholders and Encourages Investors to Contact the Firm
- NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) on behalf of Tempus stockholders. Our investigation concerns whether Tempus has violated the federal securities laws and/or engaged in other unlawful business practices.
- 06/04/2025
|
Did You Suffer Losses in Tempus AI, Inc. (TEM)? Contact Levi & Korsinsky About Securities Fraud Claims
- NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/04/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
- NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ:TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/04/2025
|
Fraud Investigation: Levi & Korsinsky Investigates Tempus AI, Inc. (TEM) on Behalf of Shareholders
- NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/04/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Tempus AI, Inc. (TEM) And Encourages Investors to Connect
- NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 06/04/2025
|
Lost Money on Tempus AI, Inc. (TEM)? Contact Levi & Korsinsky to Protect Your Rights
- NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/03/2025
|
Levi & Korsinsky Investigates Tempus AI, Inc. (TEM) Over Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/03/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages Tempus AI, Inc. (TEM) Stockholders to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 06/03/2025
|
TEM Investor Notice: Levi & Korsinsky Investigates Tempus AI, Inc. for Securities Law Violations
- NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/03/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
- NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc.("Tempus" or the "Company") (NASDAQ:TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/03/2025
|
Why Tempus AI Stock Soared 15% Today
- Shares of Tempus AI (TEM 14.71%) soared on Monday. The company's stock jumped 15% as of market close.
- 06/02/2025
|
Levi & Korsinsky Investigating Whether Tempus AI, Inc. (TEM) Misled Investors - Securities Law Violations Possible
- NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 06/02/2025
|
TEM ALERT: Ongoing Investigation Into Tempus AI, Inc. - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 05/31/2025
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
- NEW YORK CITY, NY / ACCESS Newswire / May 31, 2025 / WHY: New York, N.Y., May 31, 2025.
- 05/31/2025
|
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus' proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests desi.
- 05/31/2025
|
Levi & Korsinsky Investigates Tempus AI, Inc. (TEM) Over Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 05/30/2025
|
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Tempus AI Inc. (NASDAQ: TEM) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
- NEWTOWN, Pa., May 30, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Tempus AI, Inc. (NASDAQ: TEM), resulting from allegations of providing potentially misleading business information to the investing public.
- 05/30/2025
|
Rosen Law Firm Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
- NEW YORK , May 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public. So What: If you purchased Tempus AI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/30/2025
|
Tempus AI Stock: Buy the Dip, or Is the Short-Seller Right?
- In this video, I will talk about Tempus AI (TEM 2.65%) and the recent short-seller report. Watch the short video to learn more, consider subscribing, and click the special offer link below.
- 05/30/2025
|
ATTENTION TEM Shareholders: Lost Money on Tempus AI, Inc.? Contact Levi & Korsinsky About Investigation
- NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 05/30/2025
|
Why Tempus AI Stock Plummeted This Week
- Extending the more-than-4% slide that they experienced last week, shares of Tempus AI (TEM 2.63%) have suffered an even more precipitous decline this week. According to data provided by S&P Global Market Intelligence, the healthcare-oriented artificial intelligence (AI) stock had fallen 13.2% from the end of last Friday's trading session through the market's close on Thursday.
- 05/30/2025
|
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 - June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company's use of AI-driven solutions.
- 05/30/2025
|
TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
- NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public.
- 05/29/2025
|
Tempus AI, Inc. Investors: Company Investigated by the Portnoy Law Firm
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 05/29/2025
|
Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King' (UPDATED)
- Editor's note: This story has been updated to include a statement from a Tempus AI spokesperson.
- 05/29/2025
|
TEM Investor Notice: Levi & Korsinsky Investigates Tempus AI, Inc. for Securities Law Violations
- NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
- 05/29/2025
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Tempus AI, Inc. (TEM) And Encourages Investors to Reach Out
- NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 05/29/2025
|
Tempus AI, Inc. (NASDAQ: TEM) Securities Fraud Investigation; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
- OAKLAND, Calif.--(BUSINESS WIRE)---- $TEM #TEM--Gibbs Mura, A Law Group, is investigating potential legal claims on behalf of shareholders with losses in Tempus AI, Inc. (NASDAQ: TEM).
- 05/28/2025
|
TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm.
- 05/28/2025
|
Rosen Law Firm Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation – TEM
- NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public. So What: If you purchased Tempus AI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/28/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Tempus AI, Inc. – TEM
- NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 05/28/2025
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Tempus AI, Inc. (TEM) And Encourages Stockholders to Reach Out
- NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
- 05/28/2025
|
A Cathie Wood Favorite Is Falling: Why Tempus AI Stock Is Imploding Today
- Shares of Tempus AI (TEM -18.92%) are falling on Wednesday. One of Cathie Wood's largest holdings, the company's stock plummeted 18.7% as of 2:15 p.m.
- 05/28/2025
|
Why Artificial Intelligence Stock Tempus AI Is Tumbling Today
- Shares of artificial intelligence (AI) company Tempus AI (TEM -17.62%) are down to the tune of 15.6% as of 11:13 a.m. ET on Wednesday, upended by a warning from investment management outfit Spruce Point Capital Management.
- 05/28/2025
|
Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King'
- Spruce Point Capital Management has announced a new short position against Tempus AI Inc. TEM. On Wednesday, the short seller raised concerns about the company's management team.
- 05/28/2025
|
A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its participation in almost 1,500 research projects in just the last ten years. This milestone highlights Tempus' ongoing commitment to accelerating scientific discovery and delivering data-driven insights that improve patient outcomes. Since its founding in 2015, Tempus has partnered with leading academic institutions, communit.
- 05/28/2025
|
Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy?
- BFLY outpaces TEM with stronger upside, leaner valuation, and expanding global reach in AI-powered diagnostics.
- 05/26/2025
|
Tempus AI: Firing On All Cylinders
- Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting revenue and backlog. The AI precision medicine company grew core revenues 32% YoY, but headline growth topped 75% due to the Ambry deal, though organic growth analysis is crucial for investors. The stock trades at a reasonable 7x '26 sales with 25-28% pro forma growth, but limited adjusted EBITDA targets may cap the valuation premium.
- 05/25/2025
|
These Investors Search for ‘Extreme Winners.' Why Aurora, BYD, Tempus AI Make the Cut.
- Lingotto Innovation's James Anderson and Morgan Samet favor companies with explosive growth potential and a focus on innovation.
- 05/23/2025
|
Tempus AI: I Believe In The Company's Cause
- I initiate coverage of Tempus AI, Inc. with a Buy rating, driven by its unique data assets and AI-powered oncology solutions. The company posted strong revenue growth and margin expansion, though profitability and high debt remain concerns as it integrates recent acquisitions. Tempus AI's vast clinical and molecular data, validated at major conferences, positions it as a key partner for leading pharma and healthcare companies.
- 05/22/2025
|
Tempus to Present at the William Blair 45th Annual Growth Stock Conference
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference. The event will take place from June 3-5 in Chicago, IL. Jim Rogers, Chief Financial Officer of Tempus, will present on June 5. A live audio webcast of the presentation will be available here. About Tempus Tempus is a technology company advancing precision medicine throug.
- 05/21/2025
|
Tempus: Is This Ultra-Fast-Growing Company A Good Investment?
- Tempus AI, Inc. is growing rapidly in healthcare tech, especially genomics, but is not yet profitable and carries significant risk. Recent revenue growth is boosted by the Ambry Genetics acquisition; organic growth remains strong, but future growth may slow post-acquisition. The company benefits from exposure to large, expanding markets and leverages AI/data partnerships, but faces high valuation multiples.
- 05/20/2025
|
These 3 AI-Related Stocks Crushed Earnings
- Earnings season continues to move rapidly, with many companies unveiling quarterly results daily. So far, the period has been positive, though it's worth noting that estimates for the current period (Q2) have trickled lower in recent weeks.
- 05/20/2025
|
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers. Tempus completed confirmatory testing in Verastem's Phase 2 RAMP-201 clinical trial, which evaluated the combinati.
- 05/20/2025
|
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?
- President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI.
- 05/15/2025
|
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim's growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic research and development. Despite significant breakthroughs in the un.
- 05/14/2025
|
Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape, and Forecasts Report 2025-2032 Featuring Key Players Such as TEMPUS, NetraMark, ConcertAI, AiCure, and Oracle
- The AI in Clinical Trials Market is driven by the surge in chronic diseases and increased pharma collaborations. Valued at $1.35 billion in 2024, it aims to reach $3.33 billion by 2032. North America leads due to investment in R&D and numerous trials. The AI in Clinical Trials Market is driven by the surge in chronic diseases and increased pharma collaborations. Valued at $1.35 billion in 2024, it aims to reach $3.33 billion by 2032. North America leads due to investment in R&D and numerous trials.
- 05/14/2025
|
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal, Canada. Tempus researchers are showcasing scientific and clinical studies highlighting the impact of AI and real-world data.
- 05/13/2025
|
Big Earnings Beats: 6 Stocks That Spiked After Reporting Results
- We're winding down earnings season, and the old Wall Street adage that “earnings drive stock prices” continues to prove true.
- 05/13/2025
|
These AI Stocks Posted Robust Results: Time to Buy?
- Several AI-related stocks have posted robust results throughout the Q1 earnings cycle, a list that includes Palantir and Tempus AI. Given their results, it's impossible to deny the staying power of AI, which is still likely in its early innings.
- 05/09/2025
|
Tempus AI Stock: Time to Double Down or Cut and Run?
- Tempus AI NASDAQ: TEM is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-treat illnesses and pharmaceutical companies like AstraZeneca NASDAQ: AZN, with advances in medicine impossible without computerized assistance.
- 05/08/2025
|
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals
- JP Morgan analyst Rachel Vatnsdal reiterated the Neutral rating on Tempus AI, Inc. TEM on Wednesday, with a price forecast of $55.
- 05/07/2025
|
Tempus AI, Inc. (TEM) Q1 2025 Earnings Call Transcript
- Tempus AI, Inc. (NASDAQ:TEM ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Liz Krutoholow – Vice President-Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Ryan MacDonald – Needham & Company Mark Schappel – Loop Capital Subbu Nambi – Guggenheim Daniel Brennan – TD Cowen Mark Massaro – BTIG Michael Ryskin – Bank of America Rachel Vatnsdal – JPMorgan Dan Arias – Stifel Operator Good day everyone. And thank you for standing by.
- 05/06/2025
|
Tempus Reports First Quarter 2025 Results
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic.
- 05/06/2025
|
TEMPUS (Nasdaq: TEM) Earnings: Live Coverage And What to Expect
- Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today.
- 05/06/2025
|
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients' electronic health records. Notetaker complements Tempus'.
- 05/05/2025
|
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
- When it comes to shares of Tempus AI (TEM 0.31%), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this.
- 05/02/2025
|
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the T.
- 05/01/2025
|
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers,.
- 04/29/2025
|
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?
- TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.
- 04/28/2025
|
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus' proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI to rapidly uncover insights for pre-clinical therapeutic de.
- 04/28/2025
|
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment an.
- 04/25/2025
|
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
- Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI's de-identified oncology data.
- 04/24/2025
|
Tempus to Report First Quarter 2025 Financial Results on May 6
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible.
- 04/24/2025
|
Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now?
- Amid a bullish backdrop for the broader market, Tempus AI (TEM 17.72%) stock is posting big gains Wednesday. The company's share price was up 15.8% as of 1:45 p.m.
- 04/23/2025
|
Discover Why Quantum Computing Stocks Are Soaring Today
- With the stock market in rally mode, there are more pockets of strength than there have been in a while.
- 04/23/2025
|
Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos
- Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop what it called the largest multimodal foundation model in oncology, sending its shares up more than 15% in morning trading. The deals, which include $200 million in data licensing and model development fees to Tempus, will leverage the company's vast repository of de-identified oncology data and artificial intelligence capabilities to help identify new drug targets and advance cancer therapies.
- 04/23/2025
|
Why Tempus AI Stock Is Skyrocketing Today
- Shares of Tempus AI (TEM 17.39%) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday.
- 04/23/2025
|
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology.
- 04/23/2025
|
Why Quantum Computing (QUBT), Nano Nuclear Energy (NNE) and Tempus AI (TEM) Are Popping Higher Today
- Analysts at BTIG initiated coverage of TEM with a buy rating with a price target of $60.
- 04/22/2025
|
Tempus AI: Cooldown Arrived (Rating Upgrade)
- Tempus AI is trading near yearly lows despite strong growth prospects, driven by the Ambry Genetics acquisition and robust organic growth. The company has innovative AI diagnostic services, including new cancer tests and CMS-approved algorithms, positioning it for continued 25% annual growth. TEM stock has a market cap of ~$7 billion and trades at 4.5x sales, offering compelling value and growth potential for investors.
- 04/22/2025
|
Investment strategist picks 3 ‘new age' healthcare stocks to buy
- Investment strategist Shay Boloor has highlighted three companies driving the “new age” of healthcare, making them must-watch opportunities for investors.
- 04/20/2025
|
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals is providing guidance, expertise.
- 04/18/2025
|
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
- Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.
- 04/15/2025
|
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?
- Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment?
- 04/11/2025
|
Is it safe to buy the Tempus AI stock dip now?
- Tempus AI stock price remains in a deep bear market as investors worry that the hype that drove it to a record high was ending. The TEM stock initially peaked at $91.40 in February, and has now plunged to a low of $37.2, meaning that it has dropped by 60%.
- 04/09/2025
|
Thermo Fisher Stock Benefits From the Launch of Krios 5 Cryo-TEM
- TMO launches the Krios 5 Cryo-TEM, boosting productivity and performance with enhanced automation.
- 04/04/2025
|
Thermo Fisher Scientific Launches the Krios 5 Cryo-Transmission Electron Microscope (TEM), Boosting Productivity and Performance With Enhanced Automation
- WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Krios™ 5 Cryo-TEM. This next-generation, atomic-resolution platform leverages enhanced optics and AI-enabled automation to study molecular structures and interactions at a throughput and fidelity that was previously unattainable. A Leap Forward in Imaging and Insight In the rapidly evolving field of structural biology, single particle analysis (SPA) and cryo-elec.
- 04/02/2025
|
Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock?
- The February 2025 acquisition of Ambry Genetics further expands TEM's genomics capabilities with a West Coast lab and enhanced inherited risk testing.
- 04/01/2025
|
Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus is presenting research, all of which highlights the application of AI to support clinicians in delivering personalized care. “Tempus.
- 03/29/2025
|
4 Healthcare Stocks With Massive Gains—and More to Come
- The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far.
- 03/29/2025
|
Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7-10, 2025. Tempus' Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Wednesday, April 9. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medi.
- 03/26/2025
|
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
- Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
- 03/19/2025
|
Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
- Tempus AI's financials have significantly improved, with positive cash flow expected next quarter and strong revenue growth projected for FY25. Q4FY24 saw record revenues, driven by a 35.8% YoY growth, with the Data & Services segment growing by 44.6% YoY. FY24 revenues hit an all-time high of $693.4 million, with major agreements signed and the launch of the AI-enabled health app, Olivia.
- 03/18/2025
|
Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?
- The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.
- 03/17/2025
|
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
- TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.
- 03/13/2025
|
Tempus Announces Acquisition of Deep 6 AI
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence (RWE) with speed and precision. Its AI-powered software matches pati.
- 03/11/2025
|
Should Investors Buy Tempus AI Stock Right Now?
- Tempus AI (TEM -11.18%) is utilizing artificial intelligence to deliver better healthcare outcomes.
- 02/28/2025
|
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
- The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.
- 02/26/2025
|
Tempus AI: Buying The Dip After 2025 Guidance Raise
- Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results, presenting a buying opportunity due to raised 2025 revenue guidance. The company, a leader in healthcare AI, focuses on revenue growth and customer adoption, with a proprietary data model for personalized healthcare treatment. Despite stock volatility, Tempus AI's 30% organic revenue growth and Ambry acquisition integration highlight its long-term potential in the healthcare AI market.
- 02/26/2025
|
Tempus AI Is a Buy, If You Can Handle the Volatility
- Tempus AI NASDAQ: TEM is an emerging AI player in the healthcare field with a robust outlook for long-term growth and profitability. The company uses AI to manage patient testing and help physicians generate timely diagnoses and treatment regimens.
- 02/26/2025
|
Tempus AI Down 13%- Is It Time to Buy?
- Shares of Nancy Pelosi's favorite artificial intelligence stock Tempus AI (NASDAQ:TEM) are falling more than 13% in morning trading after reporting fourth quarter and full-year 2024 earnings results yesterday after the market closed.
- 02/25/2025
|
Nancy Pelosi’s Latest AI Stock Pick Tempus AI Is Up Big Today
- Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which included $375 million in cash payments and $225 million in shares. Key Points About Article Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM stock by buying 50 of the TEM January 2026 $20 call options. Tempus AI CFO Jim Rogers just sold over 31,000 shares, removing about $2.6 million of value from the stock. However, we wouldn’t read too much into the selling. Investors may want to use weakness as an opportunity. Last year we published our “The Next NVIDIA” report that called Palantir before its epic run. The free report comes with 38 pages of in-depth research on top AI stock ideas. However, it’s only available for a limited time. Click here to learn more and grab your complimentary copy. Plus, Nancy Pelosi took a stake in the TEM stock by buying 50 of the TEM January 2026 $20 call options in mid-January. Even Cathie Wood picked up about 600,000 shares across multiple funds last month. After a drop from a high of $91.45, last week the stock tumbled to $68 but has regained its composure and up 7% today so far today. Sparking the pullback, insiders have been selling. Tempus AI CFO Jim Rogers just sold over 31,000 shares, removing about $2.6 million of value from the stock. However, we wouldn’t read too much into the selling. For us, it’s not a significant cause for concern because the funds could be used for personal reasons. We also have to remember that Tempus AI is moving to revolutionize healthcare with artificial intelligence. Plus, the Ambry Genetics acquisition “complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies,” says CEO Eric Lefkofsky. The acquisition is also expected to strengthen Tempus AI’s product offerings and accelerate its road to positive free cash flow and profitability. Institutional Interest in Tempus is Still Strong At the end of 2024, Cathie Wood’s ARK Invest increased its stake in TEM by 132% by adding 3.14 million shares. Jane Street Group raised its stake by 443%. Ken Griffin’s Citadel Advisors picked up 131,800 shares. Dmitry Balyasny’s Balyasny Asset Management increased its stake by nearly 515%. Blackrock also picked up 445,900 shares. In addition, analysts at TD Cowen have a buy rating on the TEM stock with a $74 price target. TEM is also expected to present at TD Cowen’s 45th Annual Health Care Conference in early March. CFO Jim Rogers is expected to talk about TEM’s AI healthcare innovations and outlook. The post Nancy Pelosi’s Latest AI Stock Pick Tempus AI Is Up Big Today appeared first on 24/7 Wall St..
- 02/25/2025
|
Tempus Stock Falls as Q4 Earnings & Revenues Miss Estimates
- TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
- 02/25/2025
|
Tempus AI Earnings: A Promising Business, But There Are Risks
- Tempus AI's core business growth is slowing, raising doubts about its AI-led narrative and long-term sustainable growth rates. Despite impressive revenue growth projections, Tempus AI remains free cash flow negative, with concerns about its ability to convert EBITDA into free cash flow. The company's balance sheet is weak, with significant net debt and a potential need for additional capital in 2025.
- 02/25/2025
|
Tempus AI, Inc. (TEM) Q4 2024 Earnings Call Transcript
- Tempus AI, Inc. (NASDAQ:TEM ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Liz Krutoholow - Investor Relations Eric Lefkofsky - Founder & Chief Executive Officer Jim Rogers - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Mike Ryskin - Bank of America Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Doug Schenkel - Wolfe Research Andrew Brackmann - William Blair Mark Schappel - Loop Capital Dan Arias - Stifel David Westenberg - Piper Sandler Operator Thank you for standing by. My name is Jason, and I will be your conference operator for today.
- 02/24/2025
|
EARNINGS ALERT: TEM
- Tempus AI's (TEM) massive rally since its IPO last year took a step down with its latest earnings. The selling action after the company's miss is one George Tsilis attributes to a trend seen in small caps.
- 02/24/2025
|
Tempus Reports Fourth Quarter and Full Year 2024 Results
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024. Year-over-year revenue growth accelerated to 35.8% in the fourth quarter of 2024 Gross profit growth accelerated to 49.7% in the fourth quarter of 2024, led by Data and services Ended the year with $940 million in Total Remaining Contract Value and 140% net reven.
- 02/24/2025
|
Tempus AI Gears Up For Q4 Earnings After 101% YTD Surge
- Tempus AI Inc TEM will be reporting its fourth-quarter earnings on Monday. Wall Street expects a loss of 20 cents per share and $203.12 million in revenues as the company reports after market hours.
- 02/24/2025
|
3 Biotech/Healthcare Names Under $10 I Am Buying Now
- Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
- 02/21/2025
|
5 stocks Congress is buying in 2025
- The stock trading activities of US Congress members continue to draw attention, with disclosures under the STOCK Act providing insight into their investment strategies. So, in this piece, we bring you the top 5 stocks Congress is buying in 2025.
- 02/20/2025
|
Tempus to Present at TD Cowen's 45th Annual Health Care Conference
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health Care Conference on March 3-5, 2025 in Boston, MA. Tempus' Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Monday, March 3. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision.
- 02/19/2025
|
Ares Management Upsizes Tempus Debt Facilities to $560 Million
- NEW YORK--(BUSINESS WIRE)--Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent on $300 million in incremental debt financing for Tempus AI, Inc. (NASDAQ: TEM) (“Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care. The financing is intended to support Tempus' previously announced acquisition of Ambry Genetics (“Ambry”), whi.
- 02/18/2025
|
Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector
- TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Recently, they've made some interesting moves like acquiring Ambry Genetics, launching the Olivia health app, and collaborating with IFLI. TEM also has other innovative assets like xT CDx, xH tests, and enhanced Tempus One that I think position it perfectly for agentic AI diagnostics.
- 02/18/2025
|
25 Top AI Stocks That Could Boost Your Portfolio
- The artificial intelligence (AI) revolution is reshaping the global economy at an unprecedented pace, with innovations emerging across every sector from healthcare to transportation. As companies race to integrate AI capabilities into products and services, investors are keenly searching for opportunities to capitalize on this technological transformation.
- 02/18/2025
|
Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom Conference on Monday, March 3-6, 2025, held in San Francisco, CA. Tempus Founder and CEO, Eric Lefkofsky, will participate in a fireside discussion at the conference on Monday, March 3, 2025. A live webcast of the conversation will be available here. About Tempus Tempus is a.
- 02/18/2025
|
Conflicting Signals: Tempus AI's Stock Market Rally
- Tempus AI NASDAQ: TEM is a leader in precision medicine and artificial intelligence (AI) in the healthcare sector. Tempus AI's stock price has seen an increase, with gains of over 160% in the last month and almost 150% year-to-date, causing investors to surge in interest.
- 02/17/2025
|
Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). The collaboration aims to develop and make available a real-world multimodal, deidentifie.
- 02/13/2025
|
Think It's Too Late to Buy Tempus AI Stock? Here's the Biggest Reason Why There's Still Time.
- Refusing to slow down since the start of the new year, shares of Tempus AI (TEM 3.75%) have skyrocketed nearly 99% since Jan. 1. In light of the artificial intelligence (AI) stock's strong performance so far this year, prospective investors may fear there's not much share price growth potential left for Tempus, an innovator in applying AI solutions to the healthcare industry.
- 02/13/2025
|
AI Roundup: 3 Explosive AI-Adjacent Stocks to Watch in 2025
- Artificial Intelligence (AI) has dominated headlines to start the year, especially after President Donald Trump revealed a joint venture to invest "$500 billion, at least" for AI Infrastructure in the U.S. More recently, Chinese startup DeepSeek shook up the sector after its AI model beat out OpenAi -- at a significantly lower cost.
- 02/11/2025
|
Cathie Wood Is Betting Big on These 2 AI Stocks
- Cathie Wood's comeback could continue through the year as most of her Ark Invest funds come roaring back alongside the tech trade.
- 02/10/2025
|
Why Hims & Hers Health (HIMS), Tempus AI (TEM) and Teladoc (TDOC) Are Up Big Today
- Stock markets got a bit of a shock on Friday after a University of Michigan survey showed consumers are anticipating inflation to rise in 2025, potentially depressing consumer spending and dissuading the Fed from making any further cuts to interest rates.
- 02/07/2025
|
Why Tempus AI (TEM) Is Soaring Today
- And, according to Eric Lefkofsky, Founder and CEO of Tempus, the acquisition “complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies.
- 02/05/2025
|
AI Stocks Soaring Today: BigBear.ai (BBAI), Tempus AI (TEM), SoundHound AI (SOUN)
- AI stocks are red-hot today. Last night Alphabet (Nasdaq: GOOGL) reported earnings and its stock is down 8% today.
- 02/05/2025
|
Tempus AI: In Vogue, But Better To Wait For Some Retracement
- Tempus AI (TEM) has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility. A couple of days back, TEM closed the acquisition of Ambry Genetics which we view as largely positive. TEM's preliminary Q4 and FY earnings release last month didn't have too many surprises.
- 02/05/2025
|
Tempus AI stock price is not cheap: is it a good buy?
- Tempus AI stock price has rebounded this year as demand for artificial intelligence solutions jumped sharply. The TEM stock also jumped to $61 after the company completed its acquisition of Ambry Genetics.
- 02/03/2025
|
Tempus Completes Acquisition of Ambry Genetics
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. “This acquisition complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cut.
- 02/03/2025
|
Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch
- As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.
- 01/30/2025
|
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways
- BOSTON--(BUSINESS WIRE)-- #ISO27001--Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.
- 01/28/2025
|
Tempus AI: Bringing The Promise Of AI To Healthcare
- Tempus AI product lines work in concert with one another, creating a pinwheel effect as they generate data, making it more valuable over time. The company launched its 'AI-enabled personal health concierge app' called olivia, which should start to drive revenues to its AI applications business. TEM continues to have massive potential in the oncology market and other testing, which have large total addressable markets.
- 01/28/2025
|
Tempus AI Stock Before Q4 Earnings: To Buy or Not to Buy?
- TEM's Genomics unit is expected to report strong growth for the fourth quarter, banking on continued unit growth pick-up.
- 01/27/2025
|
What's Happening With Tempus AI (TEM) Stock?
- Tempus AI (NASDAQ: TEM), a healthcare technology company, saw its stock surge 45% in a week after the company announced the launch of its AI app – Olivia. TEM stock was listed on June 14, 2024, and it lost 16% of its value last year, falling from levels of $40 in mid-June to $34 by the end of the year.
- 01/27/2025
|
Health-Tech Revival: 3 Stocks Set for a Big 2025 Rebound
- The healthcare industry is undergoing rapid transformation, driven by advancements in technology, artificial intelligence, and data analytics. Companies at the forefront of this shift are redefining how healthcare providers manage data, deliver care, and enhance patient outcomes.
- 01/27/2025
|
Tempus AI: Wait For A Cooldown
- Tempus AI is a high-risk Buy due to its leading AI-enabled diagnostic platform, despite challenges in US healthcare reimbursement. The company connects with 2,500+ institutions to collect real-time clinical data on millions of cancer patients, enhancing treatment matching and clinical research. Tempus AI's three main products — Genomics, Data, and Applications — offer diagnostic tests, data licensing, and AI-driven patient-provider connections for clinical trials.
- 01/23/2025
|
TEM Stock Rises on Launch of AI-Powered Health Concierge App
- Tempus AI announces the launch of olivia, an AI-enabled personal health concierge app designed to revolutionize patient care and engagement nationwide.
- 01/23/2025
|
Tempus AI Stock Is Up 40% in January. Is It Too Late to Buy?
- In this video, I will talk about Tempus AI (TEM -3.88%), why the stock has soared recently, and if it is worth chasing. Watch the short video to learn more, consider subscribing, and click the special offer link below.
- 01/23/2025
|
Tempus AI's Flywheel Effect: Monetizing Data In Precision Medicine
- Tempus AI's scalable data ecosystem and path to profitability, with a clear trajectory to $1 billion in annual revenue, make it a compelling investment. The recent acquisition of Ambry, strategic fit, and sustainable growth rate bolster Tempus AI's operational and financial prospect. Risks include high debt, cash burn, reimbursement policy dependence, and integration challenges, but reduced cash burn could stabilize the company financially.
- 01/23/2025
|
Tempus AI: A Game-Changer in AI-Powered Healthcare
- Shares of Tempus AI Inc. NASDAQ: TEM surged 35% on Tuesday, bringing its market capitalization to $7.5 billion. The rally was driven by headline-grabbing news and strong market sentiment, underscoring the company's leadership in integrating artificial intelligence (AI) into healthcare.
- 01/22/2025
|
Here's Why This Medical AI Stock Soared 35% on Tuesday
- Tempus AI (TEM) stock had its best day on record on Tuesday after the medical tech company launched an AI-powered health concierge and former House Speaker Nancy Pelosi revealed she's bet on the stock.
- 01/21/2025
|
Why Tempus Ai Stock Is Skyrocketing Today
- Tempus Ai (TEM 33.70%) stock is seeing an explosive valuation surge in Tuesday's trading thanks to a pair of catalysts. The healthcare software company's share price was up 35.8% as of 3:15 p.m.
- 01/21/2025
|
Tempus AI Has A High Probability Of Profitability In 2025
- Tempus AI, Inc. is projected to achieve 30% YoY top line growth in Q4 2024 as presented in management's preliminary results. Growth is forecast to continue in the 23-25% range in eFY25. Tempus is expecting to close the Ambry acquisition in Q1 2025. The deal will be accretive to Tempus' adjusted EBITDA margin while maintaining its high-growth trajectory. Tempus recently gained in-network provider status with Blue Cross Blue Shield across multiple states, allowing for the firm's tests to be covered by insurance.
- 01/21/2025
|
Tempus AI jumps almost a third on health app launch
- Tempus AI Inc shares skyrocketed on Tuesday after the company announced the nationwide launch of its personal health app. Known as Olivia, the app was designed to centralize patients' health data and make it accessible and actionable using artificial intelligence, Tempus said in a statement.
- 01/21/2025
|
Tempus Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights. olivia is designed to address two core objectives – centralizing patients' health data and ma.
- 01/21/2025
|
Tempus Announces the National Launch of FDA-Approved xT CDx Test
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company's FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels available. xT CDx is a 648-gene next-gen.
- 01/15/2025
|
Tempus AI: Disappointing Q4 Preliminary Results, But Bullish Fundamental Update
- Tempus AI is a leading player in healthcare AI, aiming to deliver personalized treatment suggestions through its proprietary data model. Preliminary Q4 results and 2025 guidance show mixed performance, with revenue slightly below expectations but positive adjusted EBITDA anticipated for 2025, driven by the Ambry Genetics acquisition. TEM's strong fundamentals and competitive position, bolstered by the Ambry acquisition, support long-term growth, particularly in diagnostics and expanding AI applications across healthcare.
- 01/15/2025
|
TEM Stock Declines Following Preliminary Q4 Sales Miss
- Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.
- 01/14/2025
|
Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus' first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.
- 01/13/2025
|
2 Stocks Cathie Wood Is Swinging For the Fences With
- Investing guru Cathie Wood remains an investor favorite.
- 01/11/2025
|
Tempus AI Stock Falls Despite Collaboration Announcement With Genialis
- TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.
- 01/09/2025
|
Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus' multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict patient response to treatment.
- 01/08/2025
|
Tempus AI Stock Surges 23% in 6 Months: Should You Snap It Up Now?
- TEM's cutting-edge product lines and strategic plans are positioning it for long-term success.
- 01/07/2025
|
5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More
- Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care.
- 12/30/2024
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Cathie Wood's aggressive growth style of investing may have fallen flat earlier this year, but the co-founder, CEO, and ace stock picker at Ark Invest has been on a roll lately. Ark's most popular exchange-traded fund has soared 25% over the past three months and 36% over the past six months.
- 12/29/2024
|
Tempus AI Stock Plunges 28.9% in Three Months: What's Next?
- TEM is enhancing its offerings and expanding the breadth of products and services to improve patient care. However, macro challenges are likely to hurt its performance.
- 12/24/2024
|
Tempus AI: A Potential Double-Bagger After Recent Pullback
- In mid-August, around two months after Tempus AI's NASDAQ: TEM initial public offering (IPO), the stock was up a marvelous 93%. However, shares have experienced wild volatility and are now 8% below their opening price of $37 as of the Dec. 18 close.
- 12/20/2024
|
Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions
- CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. As part of the agreement with Avalon, Tempus is a participating provider with BCBS North Carolina, BCBS South Carolina, BCBS Vermont, Capital Blu.
- 12/18/2024
|
Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays
- Tempus AI has strong long-term potential in healthcare technology, despite recent stock volatility due to lock-up period expiration and insider selling. The company's innovative "Intelligent Diagnostics" leverages generative AI and a vast proprietary dataset to drive personalized treatment options, positioning it as a leader in precision medicine. Financially, Tempus shows robust revenue growth but remains unprofitable; recent acquisitions and ongoing investments aim to strengthen its market position and path to profitability.
- 12/17/2024
|
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm. ECG-AF is one of just a few FDA-authorized medical technologies in the country to be impacted by the new CMS decision, and this milestone all.
- 12/17/2024
|
Tempus AI: Why I'm Buying This AI Stock
- Tempus AI's strategic acquisitions and partnerships, including Ambry Genetics and a JV with SoftBank, bolster its growth and competitive edge in AI health tech. The revenue growth and gross margins for Tempus AI's Data & Services division position Tempus AI for significant future profitability and cash flow. AI-driven automation and advanced machine learning algorithms enhance operational efficiency, reducing costs and accelerating data analysis for better client insights.
- 12/08/2024
|
Will Ambry Genetics Acquisition Drive Tempus AI's Prospects?
- TEM acquires Ambry Genetics, expanding its testing portfolio and redefining precision medicine.
- 11/25/2024
|
Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York. Tempus Founder and CEO, Eric Lefkofsky, will participate in a fireside discussion at the conference on Tuesday, December 3, 2024, at 3:00 p.m. ET. About Tempus Tempus is a technology company advancing precision medic.
- 11/25/2024
|
The Big 3: CRWD, CVNA, TEM
- @ProsperTradingAcademy's Charles Moon is bullish on all of today's Big 3. He points to Crowdstrike's (CRWD) recovery and Carvana (CVNA) coiling to the upside as positive markers but warns of volatility when it comes to Tempus AI (TEM).
- 11/22/2024
|
Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
- Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecular data library, advanced AI algorithms, and strategic partnerships with pharmaceutical giants like Merck and BioNTech. Despite profitability concerns and high cash burn, Tempus AI's revenue growth, strategic acquisitions, and unique data assets create a compelling long-term investment.
- 11/12/2024
|
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DN.
- 11/11/2024
|
Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript
- Tempus AI, Inc. (NASDAQ:TEM ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Rachel Vatnsdal – JPMorgan Michael Ryskin – Bank of America Daniel Brennan – TD Cowen Ryan MacDonald – Needham Andrew Brackmann – William Blair Operator Thank you for standing by. My name is Briana, and I will be your conference operator today.
- 11/09/2024
|
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, which convenes in Houston, Texas, from November 6-10, 2024. “Presenting our latest research is a vital opportunity to showcase the advancements Tempus is making in harnessing the power of data and AI to drive im.
- 11/08/2024
|
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are already considered candidates for immune checkpoint inhibitor (.
- 11/07/2024
|
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
- TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
- 11/05/2024
|
Tempus to Report Third Quarter 2024 Financial Results on November 4
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus.
- 11/03/2024
|
Tempus: Attempting To Lead The AI Revolution In Healthcare
- Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. TEM aims to leverage AI and ML and revolutionize healthcare diagnostics, a space which has large gaps and is relatively untapped. Despite an impressive revenue profile and a burgeoning data licensing vertical, TEM remains a long way off profitability and faces high operating cash burn and SG&A expenses.
- 10/29/2024
|
Tempus to Report Third Quarter 2024 Financial Results on November 7
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast w.
- 10/24/2024
|
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
- TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.
- 09/30/2024
|
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts. After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon.
- 09/26/2024
|
Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, which convenes in Barcelona, Spain, from September 13-17, 2024. "ESMO provides a great platform to share our recent research and advancements with the global oncology community, foster further collaboration, and drive.
- 09/13/2024
|
Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data. olivia, which is currently only available to beta users, leverages generative AI to provide patients and their caregivers persona.
- 09/12/2024
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Cathie Wood bought shares of AMD, DraftKings, and Tempus AI on Tuesday. AMD is growing its data center and AI chips business, but it's struggling badly in other segments.
- 09/11/2024
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Cathie Wood bought shares of Tempus AI, Blade Air Mobility, and Absci on Thursday. Tempus AI was a broken IPO shortly after going public two months ago, but it soared 34% in August.
- 08/30/2024
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Cathie Wood bought shares of DraftKings, Shopify, and Tempus AI on Monday. DraftKings is boosting its revenue guidance, but having to backtrack on a player surcharge isn't a good look.
- 08/27/2024
|
Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +
- In this article, Seeking Alpha editors highlight 12 ideas published last week focused on stocks with less coverage on our platform. Energy ideas are prevalent in this edition with articles highlighted on uranium development, oil & gas, and clean energy companies. Healthcare-related stocks are in focus as well, with a couple of biotech picks, a skilled nursing facility operator, and a healthcare technology company included.
- 08/23/2024
|
Biotech Stock Soars 60% in 2024: Cathie Wood's Bold Investment
- In just ten days, shares of the mid-cap healthcare stock Tempus AI NASDAQ: TEM have gone from down 4% to up nearly 60% in 2024. Famed investor Cathie Wood recently increased her allocation to the company through the ARK Invest family of funds.
- 08/23/2024
|
Why Tempus AI Stock Skyrocketed Nearly 22% Today
- The recently listed company expanded its shareholding in a biotech. It now owns over 19% of biotech Personalis' common equity.
- 08/21/2024
|
Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'
- Tempus AI provides an end-to-end diagnostic platform connecting clinical, molecular, and image data for physicians and pharmaceutical companies. The company's key competitive advantages include broad data collection, a genomics platform, and intelligent diagnostics, positioning Tempus uniquely in the healthcare technology industry. Recent financial results show 25% year-over-year revenue growth, with Softbank's investment indicating disruptive potential in healthcare diagnostics and precision medicine.
- 08/21/2024
|
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
- BERGEN, Norway , Aug. 21, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update. Highlights, including post period: BGBC016 1L NSCLC STK11m study continues to progress as planned.
- 08/21/2024
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Cathie Wood of Ark Invest bought millions of dollars worth of shares recently. Amazon was a key purchase across most of her funds.
- 08/20/2024
|
3 Stocks for the AI Age
- We all know by now that compound interest is hard to visualize. As early as 1256 AD, storytellers began recording the wheat and chessboard problem.
- 08/18/2024
|
Tempus AI Soars To New Highs, Investments From Google And SoftBank Boost Bullish Sentiment
- Tempus AI Inc. TEM, a cutting-edge healthcare diagnostics company, has been on a tear. The stock established a new high of $47.81 on Thursday.
- 08/16/2024
|
7 Growth Stocks to Buy on Corrections for 3X Returns by 2026
- The S&P 500 index touched highs of 5,670 in July. Over the last one month, the index movement has been volatile with a downward bias.
- 08/15/2024
|
7 Growth Stocks That Could 7X in the Next 7 Years
- The recent market correction is a reminder to investors that it's important to remain grounded even during bull markets. By this, I imply having a balanced portfolio and staying away from overvalued stocks.
- 08/08/2024
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Wood added to her positions in Amazon, Tesla, and Tempus AI on Monday. Amazon has seen its stock fall since posting poorly received results last week, but it's still a leader.
- 08/06/2024
|
3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns
- Global markets are down as fears of an economic downturn triggered a near-term crisis. This is a reminder that corrections can come from most unexpected events.
- 08/06/2024
|
3 AI-Powered Healthcare Stocks Transforming Medicine
- AI healthcare stocks can potentially revolutionize patient care as we know it. The groundbreaking technology is expected to have a pervasive impact on the investment world, with its most profound anticipated transformations in healthcare.
- 08/02/2024
|
7 New Growth Stock Listings That Can Be Long-Term Wealth Creators
- The initial public offering (IPO) and the subsequent listing is one of the best times to buy new growth stocks. The markets are still in a phase of understanding the business potential and there is limited analyst coverage.
- 08/02/2024
|
3 AI-in-Healthcare Stocks to Buy for Outsized Returns
- Across industries, companies will need to adopt AI for growth and survival. A PricewaterhouseCoopers indicates that by 2030, AI could contribute up to $15.7 trillion to the global economy.
- 07/29/2024
|
7 Growth Stocks That Can Create Millionaires by 2030
- In June 2010, Tesla (NASDAQ: TSLA ) was listed with a market valuation of $2.23 billion. Currently, the EV maker commands a market valuation of $785 billion.
- 07/26/2024
|
7 Millionaire-Making Growth Stocks to Buy and Forget
- Before entering the markets, investors need to clearly define their objective. If the idea is to take low-risk and beat inflation, it makes sense to go overweight on blue-chip stocks trading at attractive valuations.
- 07/18/2024
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Shopify stock is down, but the e-commerce software platform remains a dominant player. Oklo, a recent IPO backed by Sam Altman, aims to provide clean and affordable energy.
- 07/18/2024
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Cathie Wood bought shares of Shopify, Blade Air Mobility, and Tempus AI on Monday. Shopify and Blade Air are trading lower in 2024.
- 07/16/2024
|
3 Under-the-Radar IPO Stocks to Buy Before They Double
- With the S&P 500 index trading near all-time highs, the initial public offering market has been robust. It's also not uncommon that quality IPO stocks remain under-the-radar for a while before surging higher as it catches analyst and investor attention.
- 07/15/2024
|
Tempus AI Has Massive Market Opportunity For This Healthcare Technology, Bullish Analyst Says
- William Blair initiated coverage on Tempus AI, Inc TEM, citing the company's ‘differentiated approach and business model.'
- 07/09/2024
|
Why Wall Street Is Bullish on Healthcare Tech Stock Tempus AI
- Several analysts kicked off coverage of Tempus AI (TEM) with bullish comments, anticipating gains from the biotech company's applications of artificial intelligence (AI) to healthcare.
- 07/09/2024
|
AI-boosted medical diagnostics firm Tempus AI given 'buy' rating
- Tempus AI (NASDAQ:TEM), a provider of AI-enabled precision medicine, has been initiated with a 'buy' rating by Bank of America, which likes how the company combines a patient's molecular, clinical and other data to provide a new level of medical diagnostics. There are other companies that provide similar molecular diagnostics – Guardant Health, Foundation Medicine, NeoGenomics (NASDAQ:NEO) for three – Tempus differs from most of them by adding layers of additional patient information such as MRI imaging data, patient records, as well as AI techniques such as neural networks, deep learning, and large language models.
- 07/09/2024
|
TD Cowen's Dan Brennan on why he's bullish on Tempus
- Dan Brennan, senior analyst at TD Cowen, joins CNBC's 'The Exchange' to discuss his price target on Tempus, AI in diagnostics, and more.
- 07/09/2024
|
Buy this healthcare company's stock because it's an AI play, analysts say
- A number of Wall Street analysts on Tuesday made bullish calls on the shares of a newly public healthcare company that uses artificial intelligence to differentiate itself in the cancer-diagnostics space.
- 07/09/2024
|
Wall Street analysts bullish on genetic testing firm Tempus AI
- Wall Street brokerages started covering SoftBank Group-backed Tempus AI on a bullish note on Tuesday, betting that the company's AI-powered library of clinical and molecular data could lead to more powerful diagnostic and test kits.
- 07/09/2024
|
IPO Watch: 3 New Stocks Worth a Strong Look
- The market for initial public offerings (IPOs), featuring promising new IPOs, has rebounded strongly in 2024, with the number of offerings surpassing last year's total by 40%. The combined valuation of this year's IPOs has more than doubled compared to the previous year, sparking speculation about future public offerings.
- 07/05/2024
|
SoftBank Group launches AI healthcare joint venture with Tempus AI
- Japanese technology investor SoftBank Group has launched a joint venture with Tempus AI that aims to analyse personal medical data with artificial intelligence (AI) to come up with treatment recommendations.
- 06/27/2024
|
Revere Payments Named BigCommerce Preferred Technology Partner
- PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Revere Payments helps fast-growing BigCommerce customers streamline payment processes and improve transaction security and enhance customer experience.
- 06/26/2024
|
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF). This is the first FDA clearance for an AF indication in the category known as “cardiovascular machine learning-based notification software” and paves.
- 06/26/2024
|
Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotechnology company focused on providing a brighter future for patients through the development of novel pharmaceuticals and technologies. As part of this collaboration, Tempus will develop and investigate AI-based medical device software to detect patients at risk of having undiagnosed pulmonary hyper.
- 06/25/2024
|
Google Invested in This Hot New Artificial Intelligence (AI) Stock. Should You?
- Tempus AI conducted its IPO last week. The healthcare AI company has financial backing from Google.
- 06/19/2024
|
Tempus IPO: Stock price watched today as AI health-tech company starts Nasdaq trading
- Nothing is hotter in tech right now than artificial intelligence. No wonder then that many AI companies see 2024 as the year to go public.
- 06/16/2024
|
U.S. IPO Weekly Recap: Precision Medicine IPO Tempus AI Posts A Modest Gain In Its Debut
- One large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading - Tempus AI, Telix Pharmaceuticals, Centurion Acquisition, and Perceptive Capital Solutions, respectively. One nanocap is currently scheduled to list in the week ahead, although some other small issuers may join the calendar throughout the week - Nova Minerals. Street research is expected for one company in the week ahead, and lock-up periods will be expiring for one company.
- 06/15/2024
|
Tempus AI: Healthcare AI Play Faces Some Challenges From The Start
- Tempus AI, Inc, aims to revolutionize precision medicine with AI technology and healthcare data. The promise looks good, as the revenue base is substantial, but unfortunately the same applies to the losses incurred. With revenue growth slowing down dramatically and operating leverage coming to a standstill, I am leaning cautious about Tempus here.
- 06/14/2024
|
Tempus AI Surges in Nasdaq Debut Following IPO
- Shares of healthcare technology firm Tempus AI surged Friday as they began trading on the Nasdaq.
- 06/14/2024
|
Tempus AI shares soar in Nasdaq debut
- SoftBank Group-backed Tempus AI shares surged over 15% after its Nasdaq debut Friday, valuing the AI-driven genetic testing company at around $6.6 billion. The stock opened at $40 per share and rose to trade around $42.30 by midday, compared to the initial public offering (IPO) price of $37.
- 06/14/2024
|
Tempus AI shares jump 8% in Nasdaq debut
- Shares of SoftBank Group-backed Tempus AI rose 8.1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6.6 billion.
- 06/14/2024
|
TEM Stock IPO: 7 Things to Know as Tempus AI Starts Trading Today
- One of the season's most highly anticipated initial public offerings (IPOs) is taking place today. Tempus AI (NASDAQ: TEM ), a company bringing artificial intelligence (AI) to the data processing space, begins trading today after weeks of anticipation.
- 06/14/2024
|
Tempus AI CEO Eric Lefkofsky on going public: It's been an incredible journey
- Tempus AI founder and CEO Eric Lefkofsky joins 'Squawk Box' to discuss taking the company public on Nasdaq later today, the origin of the company,
- 06/14/2024
|
Tempus AI announces pricing of US IPO
- SoftBank Group-backed Tempus AI announced on Thursday the pricing of its initial public offering of 11.1 million ordinary shares at a price of $37 apiece.
- 06/13/2024
|
Tempus Announces Pricing of Initial Public Offering
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37.00 per share. All of the shares of Class A common stock are being offered by Tempus. The gross proceeds to Tempus from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Tempus, are expected to be $410.7 million. In addition, Tempus has granted t.
- 06/13/2024
|
TEM Stock IPO: When Does Tempus AI Go Public? What Is the Tempus AI IPO Price Range?
- Tempus AI stock is preparing for an initial public offering ( IPO ) and we have all of the details that traders need to know about before it gets here. Let's get into all of the latest Tempus AI IPO details below ahead of its potential listing this week!
- 06/10/2024
|
Healthcare-technology company Tempus AI looks to raise $400 million in IPO
- Tempus AI Inc. is about to give investors a way to play the intersection of medicine and artificial intelligence.
- 06/05/2024
|
Tempus AI seeks up to $6.1 bln valuation in US IPO
- Tempus AI is targeting a valuation of up to $6.10 billion in its initial public offering in the United States, the genetics testing company said on Wednesday.
- 06/05/2024
|
Billionaire Groupon founder Lefkofsky is back with another IPO: AI healthtech Tempus
- Eric Lefkofsky knows the public listing rodeo well and is about to enter it for a fourth time. The serial entrepreneur, whose net worth is estimated at nearly $4 billion, has already taken three businesses he's founded public.
- 05/30/2024
|
U.S. IPO Weekly Recap: Specialty Insurer Bowhead Sole IPO To Debut As More Names Join The Pipeline
- Specialty property & casualty insurer Bowhead Specialty Holdings priced its upsized IPO at the top of the range to raise $128 million at a $551 million market cap. Three IPOs submitted initial filings this past week. The May IPO market is expected to end on a quiet note, with no IPOs currently scheduled for the short Memorial Day week.
- 05/27/2024
|
